Skip to main content
HR 4322 116th Congress House Health Alternative treatments Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Drug, alcohol, tobacco use Emergency medical services and trauma care Government studies and investigations Health care quality Health information and medical records Health programs administration and funding Higher education Medical research Public-private cooperation Research administration and funding Research and development

Expanding Cannabis Research and Information Act

Introduced: September 12, 2019 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 2, 2019
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Sep 13, 2019
Referred to the Subcommittee on Health.
Sep 12, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 12, 2019
Introduced in House
 Plain-English summary Congressional Research Service

Expanding Cannabis Research and Information Act

This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription.

The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis.

Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

What's happening now October 2, 2019

Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Democratic 1